¹⁸F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.

Abstract

To investigate the predictive value of pretreatment ¹⁸F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers for pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). This retrospective study included 19 patients with locally advanced ESCC who underwent nCRT followed by surgery at Shandong Cancer Hospital from March 2022 to May 2023. Pretreatment clinical baseline data, ¹⁸F-NOTA-FAPI-04 PET/CT metabolic parameters, and hematological biomarkers were collected. Univariate and multivariate logistic regression analyses were used to select predictive parameters. A logistic regression model was constructed to predict pCR, and its performance was evaluated using receiver operating characteristic (ROC) curves, decision curves, and a nomogram. Among 19 patients, 11 achieved pCR, and 8 achieved non-pCR status. Univariate and multivariate analyses identified metabolic tumor volume (MTV) (OR = 0.978, p = 0.017) and platelet count (PLT) (OR = 1.003, p = 0.016) as independent predictors of pCR. By fitting a logistic regression model, the two-parameter joint model reached an AUC of 0.909, which was significantly better than the single indicator (MTV, AUC = 0.716; PLT, AUC = 0.761). The nomogram demonstrated that lower MTV (optimal threshold  ≤ 27.47) and higher PLT (optimal threshold  ≥ 330.5) values were associated with a higher likelihood of pCR. Pretreatment ¹⁸F-NOTA-FAPI-04 PET/CT-derived MTV combined with PLT can noninvasively predict pCR after nCRT in ESCC patients, providing a basis for personalized treatment strategies.